Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 19;8(7):e68869.
doi: 10.1371/journal.pone.0068869. Print 2013.

Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai, India

Petros Isaakidis  1 , Roma Paryani, Samsuddin Khan, Homa Mansoor, Mamta Manglani, Asmaa Valiyakath, Peter Saranchuk, Jennifer Furin
Affiliations

Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai, India

Petros Isaakidis et al. PLoS One. .

Abstract

Background: Little is known about the treatment of multidrug-resistant tuberculosis (MDR-TB) in HIV-co-infected adolescents. This study aimed to present the intermediate outcomes of HIV-infected adolescents aged 10-19 years receiving second-line anti-TB treatment in a Médecins Sans Frontières (MSF) project in Mumbai, India.

Methods: A retrospective review of medical records of 11 adolescents enrolled between July 2007 and January 2013 was undertaken. Patients were initiated on either empirical or individualized second-line ambulatory anti-TB treatment under direct observation.

Results: The median age was 16 (IQR 14-18) years and 54% were female. Five (46%) adolescents had pulmonary TB (PTB), two (18%) extrapulmonary disease (EPTB) and four (36%) had both. Median CD4 count at the time of MDR-TB diagnosis was 162.7 cells/µl (IQR: 84.8-250.5). By January 2013, eight patients had final and 3 had interim outcomes. Favourable results were seen in four (36.5%) patients: one was cured and three were still on treatment with negative culture results. Seven patients (64%) had poor outcomes: four (36.5%) died and three (27%) defaulted. Three of the patients who died never started on antiretroviral and/or TB treatment and one died 16 days after treatment initiation. Two of the defaulted died soon after default. All patients (100%) on-treatment experienced adverse events (AEs): two required permanent discontinuation of the culprit drug and two were hospitalized due to AEs. No patient required permanent discontinuation of the entire second-line TB or antiretroviral regimens.

Conclusions: Early mortality and mortality after default were the most common reasons for poor outcomes in this study. Early mortality suggests the need for rapid diagnosis and prompt treatment initiation, and adolescents might benefit from active contact-tracing and immediate referral. Default occurred at different times, suggesting the need for continuous, intensified and individualized psychosocial support for co-infected adolescents. Operational research among co-infected adolescents will be especially important in designing effective interventions for this vulnerable group.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flowchart of the Mumbai HIV/MDR-TB co-infected adolescent cohort, 2007–2013.
See this image and copyright information in PMC

References

    1. World Health Organization (2008) Anti-tuberculosis drug resistance in the world Report no. 4. Geneva, Switzerland. ISBN 978 92 4 156361 1: WHO/HTM/TB/2008.394.
    1. World Health Organization (2011) Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015 Geneva, Switzerland. ISBN: 978 92 4 150133: WHO/HTM/TB/2011.3.
    1. Seddon JA, Hesseling A, Willemse M, Donald PR, Schaaf HS (2011) Culture-Confirmed Multidrug-Resistant Tuberculosis in Children: Clinical Features, Treatment, and Outcomes. Clin Infect Dis. doi: 10.1093/cid/cir772. - DOI - PubMed
    1. Schaaf HS (2007) Drug-resistant tuberculosis in children. S Afr Med J 97: 995–97. - PubMed
    1. Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford N (2012) Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. The Lancet Infectious Diseases. 12(6): 449–56. - PubMed

Substances